Chemokine expression in murine experimental allergic encephalomyelitis
about
Aggregation of RANTES is responsible for its inflammatory properties. Characterization of nonaggregating, noninflammatory RANTES mutantsCytokine and Growth Factor Activation In Vivo and In Vitro after Spinal Cord InjuryCrystal structure of chemically synthesized [N33A] stromal cell-derived factor 1alpha, a potent ligand for the HIV-1 "fusin" coreceptorPlasma biomarkers discriminate clinical forms of multiple sclerosisThe chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.Increased Transendothelial Transport of CCL3 Is Insufficient to Drive Immune Cell Transmigration through the Blood-Brain Barrier under Inflammatory Conditions In Vitro.Chemokine receptor antagonism as a new therapy for multiple sclerosis.The ribonuclease protection assay: a powerful tool for the veterinary pathologist.Neutrophil-related factors as biomarkers in EAE and MS.Stromal cell-derived factor 1 (SDF-1) and antenatal human B cell lymphopoiesis: expression of SDF-1 by mesothelial cells and biliary ductal plate epithelial cellsCell therapy for multiple sclerosis.Distinct roles for IP-10/CXCL10 in three animal models, Theiler's virus infection, EAE, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10.Simvastatin ameliorates experimental autoimmune encephalomyelitis by inhibiting Th1/Th17 response and cellular infiltration.Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune EncephalomyelitisSubcutaneous Transplantation of Neural Precursor Cells in Experimental Autoimmune Encephalomyelitis Reduces Chemotactic Signals in the Central Nervous SystemThe Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune diseaseImmune cell migration as a means to control immune privilege: lessons from the CNS and tumors.Astrocytes--friends or foes in multiple sclerosis?G protein-coupled receptors as therapeutic targets for multiple sclerosis.Transplantation of autologous adipose stem cells lacks therapeutic efficacy in the experimental autoimmune encephalomyelitis modelThe multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease.Astrocyte phenotypes and their relationship to myelination.Interferon regulatory factor 1 is an essential and direct transcriptional activator for interferon {gamma}-induced RANTES/CCl5 expression in macrophages.Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis.Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor.CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis.17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis.Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia.Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression. Implications for brain inflammation.Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis.Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.Tocotrienol-rich fraction attenuates UV-induced inflammaging: A bench to bedside study.Identification of CSF-1 as a brain macrophage migratory activity produced by astrocytes.The relative number of macrophages/microglia expressing macrophage colony-stimulating factor and its receptor decreases in multiple sclerosis lesions.Digitized image analysis reveals diffuse abnormalities in normal-appearing white matter during acute experimental autoimmune encephalomyelitis.Chemokines and chemokine receptors in inflammation of the CNS.Role of chemokines, neuronal projections, and the blood-brain barrier in the enhancement of cerebral EAE following focal brain damage.A key role for ICAM-1 in generating effector cells mediating inflammatory responses
P2860
Q22010387-4AA83703-A89E-4FAB-920D-FDFEB1491405Q26740237-48A73BAC-C4B4-488F-99D1-160807961E3EQ27758437-41EE0E69-9776-441B-9679-DFF7385D9B00Q28262774-900CFB8B-9FED-49B4-B411-7730C5260F18Q33595360-D5AFE200-CDBE-48F6-9E59-3A4819A86790Q33775611-737E6CA5-7F64-4773-B3FF-744DE9A41C04Q34074854-40654E16-BB12-4509-9F4D-A7DD25347038Q34725143-760763E7-011C-4245-BD0B-58699A8161F7Q34924709-2657153E-121A-48AE-A41D-C23901F3B2ACQ35556429-A827BD74-7454-4C65-843D-11D7F06210E0Q35648117-69040F99-5DE4-456B-89D4-B6A1A5E753AAQ35648177-467E3F17-E100-4EB7-AAED-10E6B62374F2Q35838945-9E13F4CE-EF86-489F-A50A-9D5D76F81350Q36261303-8330CBCC-5FC5-4175-8680-41F93472049FQ36362639-212E8B1F-CE10-476B-9386-E7F88441FCA9Q36537921-7C504BF6-FB51-48B4-AAB1-24B986649499Q36593767-678A8BC5-608E-499E-8C65-70FD317A58BEQ36878427-24888AA1-7565-4C87-A518-60FBDA95497FQ37112554-1ADAFB06-6026-4F6F-B1DF-7A046F52D50AQ37499253-F48B7DC8-2E7B-463C-926A-DD08A51BB12FQ37760665-52F85CD6-F5C8-4939-B96F-BF69F6EA57A9Q37865581-E0167026-BF66-4630-AE82-DF1AD998DD1BQ40429375-B9E0CE0D-239D-4428-99ED-BC49A87F9106Q40970857-1A1F903C-A11B-40E2-87B2-D6AE288B53F0Q41032296-DB995D09-5714-46EF-8D64-03860C9CC499Q41360196-CB1A9FD6-4DC4-4B90-BE3C-A8CB11E8DD26Q42509922-A3D9C3B3-F5BB-4FDC-BE1C-D9A70E59F390Q43849905-B9C144C6-2656-4C57-AE09-A1C7421A70C1Q44060393-D84835E2-92AE-4E45-BBF6-BE43E1319B13Q44097403-369B0CE9-4E9D-407F-8760-13CD768ED38CQ45861565-378380BF-95CD-4551-BC77-CDE6DDEB4207Q47719808-D256110B-DD53-45F3-8239-DF8DFA163511Q48282926-3BBB4A20-1A31-41AC-9D5F-73FC047AF483Q48399318-2A3329A5-62D9-4150-BAEC-354F2C9BEF81Q48484747-889B674E-9FA6-422A-9729-F5E24423F7A2Q48589451-F59F431E-E3CE-47CC-91A2-DE52F5686BB6Q48829652-B4F8F0B2-5584-42F1-A816-C107AB5D47E0Q49115832-DC67EBA2-E716-4FF9-87C0-7F638125D50BQ57227924-53D3CE82-B0B2-4245-8ABA-0DB93959E6BD
P2860
Chemokine expression in murine experimental allergic encephalomyelitis
description
im Mai 1995 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 May 1995
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 1995
@uk
name
Chemokine expression in murine experimental allergic encephalomyelitis
@en
Chemokine expression in murine experimental allergic encephalomyelitis
@nl
type
label
Chemokine expression in murine experimental allergic encephalomyelitis
@en
Chemokine expression in murine experimental allergic encephalomyelitis
@nl
prefLabel
Chemokine expression in murine experimental allergic encephalomyelitis
@en
Chemokine expression in murine experimental allergic encephalomyelitis
@nl
P2093
P1476
Chemokine expression in murine experimental allergic encephalomyelitis
@en
P2093
P304
P356
10.1016/0165-5728(95)00008-P
P577
1995-05-01T00:00:00Z